Related Experiment Video
Updated: Jun 21, 2026
Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Characteristics and Clinical Outcomes of De Novo and Acquired Uncommon Compound EGFR Mutations in Patients With
Kevin Lu1, Sandip P Patel2, Tali Azenkot2
1Department of Internal Medicine, University of California, San Diego, La Jolla, CA.
Introduction:
The optimal treatment of uncommon, compound EGFR-mutated NSCLC is poorly defined due to heterogeneous responses to targeted therapies.
Patients And Methods:
We retrospectively reviewed patient characteristics and treatment outcomes from cohorts of advanced EGFR-mutated NSCLC patients at UC San Diego Health and the American Association of Cancer Research GENIE database.
Results:
In our institutional cohort, L858R-mutated patients were significantly more likely to have a de novo compound mutation than those with exon19del (24/159 [15%] vs. 4/228 [2%], P < .01). Conversely, acquired C797S mutations more often co-occurred with exon19del after osimertinib progression compared to L858R (23/113 [20%] vs. 6/89 [7%], P < .01). In the GENIE database, 88% of patients with S768I mutations had an additional EGFR co-mutation, most commonly G719X. Osimertinib time to treatment failure (TTF) varied notably in our institutional cohort: patients with co-mutated G719X/L861Q exhibited a median TTF > 13 months, and those with G719X alone had a median TTF < 7 months.
Conclusion:
Our findings demonstrate that compound EGFR mutations comprise distinct subgroups with unique clinical characteristics and different responses to targeted therapy. For example, osimertinib may be a viable treatment for patients with compound G719X/L861Q mutations. Further characterization of these heterogeneous subgroups is warranted for identifying optimal treatment strategies as novel targeted agents emerge.
Insights
Compound EGFR mutations in non-small cell lung cancer (NSCLC) present unique challenges. Understanding these distinct subgroups is key to developing optimal targeted therapy strategies.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Optimal treatment for uncommon, compound Epidermal Growth Factor Receptor (EGFR)-mutated Non-Small Cell Lung Cancer (NSCLC) remains undefined due to varied responses to targeted therapies.
- EGFR mutations are a key driver in NSCLC, but compound mutations add complexity to treatment selection.
Purpose of the Study:
- To investigate the clinical characteristics and treatment outcomes of distinct compound EGFR-mutated NSCLC subgroups.
- To identify potential differences in targeted therapy response based on specific EGFR mutation combinations.
Main Methods:
- Retrospective review of patient data from UC San Diego Health and the American Association of Cancer Research (AACR) GENIE database.
- Analysis of patient characteristics, mutation types (de novo and acquired), and treatment outcomes, including time to treatment failure (TTF) with osimertinib.
Main Results:
- L858R mutations were more frequently associated with de novo compound mutations compared to exon19del.
- Acquired C797S mutations post-osimertinib were more common with exon19del than L858R.
- Patients with G719X/L861Q co-mutations showed longer osimertinib TTF (>13 months) than those with G719X alone (<7 months).
Conclusions:
- Compound EGFR mutations represent heterogeneous subgroups with distinct clinical features and treatment responses.
- Osimertinib may be effective for patients with compound G719X/L861Q mutations.
- Further research is needed to optimize treatment strategies for these diverse NSCLC patient populations as new targeted agents become available.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Related Concept Videos
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers